MSD acquires Harpoon for $680m to strengthen T-cell engager armoury

Set to lose Keytuda patent protection in 2028, MSD is shoring up its oncology portfolio with immunotherapies.

Jan 9, 2024 - 18:00

MSD acquires Harpoon for $680m to strengthen T-cell engager armoury

Set to lose Keytuda patent protection in 2028, MSD is shoring up its oncology portfolio with immunotherapies.

Read the original article

Tags:

Previous Article

Zealand raises DKr1.45bn to advance obesity pipeline

Biocytogen and Radiance partner for bispecific antibody-drug conjugate

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Pharmaceutical drug delivery market and systems

Pharmaceutical drug delivery market and systems

Mar 24, 2024

J&J targets generalised myasthenia gravis landscape with nipocalimab

J&J targets generalised myasthenia gravis landscape wit...

Aug 31, 2024

STAT+: Drugmakers already bet big on mRNA for cancer. Why is Biden going in, too?

STAT+: Drugmakers already bet big on mRNA for cancer. W...

Aug 25, 2023